NYSEHealth CareHealth Care EquipmentS&P MidCap 400
$319.21
-1.90 (-0.59%)
Close of Nov 06, 2026 · end-of-day data
PEN 8-K filings in 2024
Every material Form 8-K Penumbra filed with the SEC in 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Penumbra reported third-quarter 2024 revenue of $301.0 million, up 11.1% from a year earlier, and GAAP net income of $29.5 million, versus $9.2 million in the same quarter of 2023. It reiterated full-year 2024 revenue guidance of $1,180.0 million to $1,200.0 million and raised the low end of its U.S. thrombectomy growth outlook to 24% to 25%, from 23% to 25%.
Q3 2024 GAAP diluted EPS was $0.75, versus $0.23 a year earlier; non-GAAP diluted EPS was $0.85, versus $0.67.
Q3 2024 included $5.0 million in one-time expenses tied to the wind down of the Immersive Healthcare business.
Nine-month 2024 GAAP net loss was $19.7 million, including a $76.9 million impairment charge, and the company kept its 2024 revenue guidance unchanged.
Penumbra reported second-quarter 2024 revenue of $299.4 million, up 14.5% from a year earlier, but posted a GAAP net loss of $60.2 million after a $110.3 million impairment charge tied to its immersive healthcare assets. The company also lowered its full-year 2024 revenue guidance to $1,180 million to $1,200 million, down $60 million at the midpoint from $1,230 million to $1,270 million, which weighs on the outlook for shareholders.
Q2 2024 revenue of $299.4 million, up 14.5%; U.S. thrombectomy revenue rose 24.9% to $153.7 million
2024 revenue guidance cut to $1,180 million to $1,200 million from $1,230 million to $1,270 million, with the China and European businesses cited as main drivers
Non-GAAP income from operations of $31.7 million and adjusted EBITDA of $46.3 million for the quarter
Penumbra reported first-quarter 2024 revenue of $278.7 million, up 15.4% from a year earlier, and GAAP net income of $11.0 million, or $0.28 per diluted share, compared with $8.6 million, or $0.22, in the first quarter of 2023. The company reiterated its full-year 2024 revenue guidance of $1,230.0 million to $1,270.0 million, which reflects 16% to 20% growth.
Revenue of $278.7 million, up 15.4% from $241.4 million; U.S. revenue rose 22.0% while international revenue fell 0.7%.
GAAP net income of $11.0 million, or $0.28 per diluted share, versus $8.6 million, or $0.22, a year earlier.
Operating expenses included $4.8 million in non-recurring litigation-related expenses in the first quarter of 2024.
Full-year 2024 total revenue guidance of $1,230.0 million to $1,270.0 million was reiterated, and U.S. thrombectomy growth guidance of 27% to 30% was also kept.
Penumbra reported fourth-quarter 2023 revenue of $284.7 million, up 28.7%, and GAAP net income of $54.2 million, or $1.38 per diluted share, which includes a $25.5 million tax benefit from a valuation allowance release. For 2024, the company projects total revenue of $1,230.0 million to $1,270.0 million, or 16% to 20% growth, and expects U.S. thrombectomy revenue to grow 27% to 30%.
Q4 2023 revenue was $284.7 million, up 28.7%; thrombectomy revenue was $190.8 million, up 42.4%
Q4 2023 GAAP net income was $54.2 million, or $1.38 per diluted share, including a $25.5 million tax benefit
Full-year 2023 revenue was $1,058.5 million, up 25.0%, and GAAP income from operations was $73.6 million versus $6.1 million in 2022
2024 revenue is projected at $1,230.0 million to $1,270.0 million, or 16% to 20% growth over 2023
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Penumbra filing is on SEC EDGAR ↗. 8-K briefs of other companies →